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A B S T R A C T
Chronic renal failure affects all organ systems. Senses are not exception and hearing impairment is common, particu-
larly sensorineural hearing loss (SNHL). The term »SNOS of unknown origin« or »uremic deafness« is related to only a
smaller part of the cases with unclear etiology of the impairment. The study searched for SNOS in 66 chronic hemo-
dialysis (HD) patients, mean age 51.50±12.70 years. They were treated by HD for 69.70±53.80 months. The relation be-
tween the severity of the impairment and the patients’ age, duration of HD treatment (months) and a set of laboratory pa-
rameters typical for chronic HD patients was examined. The aim of the study was to detect potential causes of the
impairment. The increased hearing threshold (HT) of above 20 dB for all frequencies was found in 42 patients (mean HT
26±10.50 dB), for speaking area frequencies in 22 patients (mean HT 19.70±8.80 dB), and in 56 patients for high fre-
quencies (mean HT 41.70±19.70 dB). The significant positive correlation of HT was found only with the patients’ age
(r=0.49, p<0.01). The patients older than 45 years had higher mean HT than those younger, and those older than 65 also
had higher HT than the younger ones. Patients with pathological value of HT were significantly more common among
the older subgroup of patients, when divided according to the age at both cutoff values of 45 and of 60 years. Mean HT
did not differ significantly according to the duration of HD treatment (subgroups A- no longer than 60 months, B- from
61 to 120 months, and C- longer than 120 months). The patients with pathological HT did not differ significantly in fre-
quency among those subgroups, and the subgroups were not different according to the mean age (A- 50.30±13.20 years;
B- 51.40±12.75 years; C- 55.80±10.55 years). In conclusion, our results along with other authors’ published data report
on SNHL as very frequent finding among chronic HD patients and suggest multifactorial etiology. Accurate proportion
of those with SNHL of unknown origin is not possible to determine. Those cases are probably not caused by uremic
polyneuropathy and/or preterm vascular aging only, although those factors are likely to play crucial roles.
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Introduction
Hearing disorders are the most frequent of all human
sensorial impairments1. They make problems in social
contacts in every tenth person at the age of 65 or more,
and in every second at the age of 80 and older than
that2,3. Hearing impairment is very common in end stage
renal disease (ESRD) patients, sensorineural hearing
loss more often than conductive impairments. They oc-
cur due to damaged sensory and neural inner ear struc-
tures, sensory cells of Cortie’s organ, acoustic nerve and
structures in central nervous system. Literature data re-
port that 20–87% of ESRD patients have sensorineural
hearing loss4–9, depending on the accepted criteria and
studied groups’ features10, but significantly more fre-
quently than the age matched general population11,12.
More than 80% of chronic renal failure patients with
sensorineural hearing loss have a known cause of the
hearing impairment (ototoxic antimicrobials, diuretics,
exposure to noise, inborn or genetic otonephropathies or
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presbyacusis)4,13–15. Remaining less than 20% of the pa-
tients have impairment termed »sensorineural hearing
loss of unknown origin« or »uremic deafness«9. Uremic
toxins or unnamed endogenous16,17 or exogenous tox-
ins18,19 that also cause uremic polyneuropathy are possi-
ble etiologic agents, or it occurs due to preterm vascular
aging10.
Sensorineural hearing loss is characterized by in-
creased hearing threshold (HT) of 15–20 dB above HT
for healthy or above HT in age matched otherwise healt-
hy people with presbyacusis, commonly in high frequen-
cies area of above 2000 Hz10, equally for bone and air con-
ductivity, without so called air bone gap20.
Uremic polyneuropathy is rare in patients with glo-
merular filtration rate above 10% of normal values. Not
only the stage but also the duration of chronic renal fail-
ure plays an important role in the development of uremic
polyneuropathy. Less important is the role of age, since it
is well known that the prevalence of the disorder in-
creases with age. At the start of chronic HD treatment
two thirds of the patients have uremic polyneuropathy.
Dialysis usually gets the control over the condition or
moderately improves it. Complete cure is very seldom. It
is not quite clear whether peritoneal dialysis has better
effect on uremic polyneuropathy due to better middle
molecules clearance or because of longer preservation of
residual renal function. Only kidney transplantation en-
ables complete cure21.
Vascular or even more accurately cardiovascular dis-
eases are very common in ESRD patients22. They are
caused by traditional and nontraditional risk factors23.
ESRD patients are at increased risk of cardiovascular
mortality for 20 times in comparison with age and co-
morbidities (including diabetes mellitus) matched non
ESRD patients24. Forty to 50% of ESRD die of cardiovas-
cular diseases25, as well as more than a half of chronic di-
alysis patients24. Based upon the data the mortality of
those patients is greater than among the most patients
that suffer from malignant diseases26.
After excluding rare causes of sensorineural hearing
loss in chronic renal failure patients27,28, both in those in
predialysis stage and those undergoing dialysis, we come
to two main possible causes: uremic polyneuropathy and
preterm vascular aging. Related to that we should have
in mind that both causes were more frequent and more
manifested with increased age and duration of chronic
renal failure, and that conservative as well as dialysis
treatment could have an impact only on uremic poly-
neuropathy but not on preterm vascular aging. However,
considering the two potential causes there is no way to
explain why sensorineural hearing loss does not always
occur bilaterally.
The study reports on the prevalence of sensorineural
hearing loss in a selected group of chronic HD patients
and on the correlation of severity of the impairment with
patients’ age, HD treatment duration and with a set of
laboratory parameters characteristic for the group of pa-
tients. The aim was to detect possible causative factors
for its development.
Patients and Methods
The study included 66 ESRD patients treated with bi-
carbonate HD, three times a week, for 4–4.5 hours, using
capillary dialyzers made of cellulose diacetate or poly-
sulphone, of the surface area of 1.5–2.2 m2, of predomi-
nantly low permeability, sterilized by g-irradiation or eth-
ylene oxide, with common blood (250–300 mL/min) and
dialysate flow (500 mL/min).Water for dialysis was pre-
pared by reverse osmosis, and conductivity of below 10
µS/cm3 was ensured. Exclusion criteria were history of
exposure to noise, Alport’s syndrome and those with con-
ductive and/or mixed hearing loss confirmed by audio-
metry and tympanography. Thanks to the long duration
of chronic renal failure we presumed certain ototoxic
antimicrobials’ and diuretics’ contribution for all chronic
HD patients, considering the group homogenous regard-
ing this issue.
The patients underwent examination by the otorhy-
nolaryngologist which was familiar with the study. Tym-
panography using tympanometer AMPLAID 720 and
audiometry using audiometer AMPLAID 455 (Italy) were
performed. HT was measured for air and bone conductiv-
ity, for both ears, for frequencies of 250, 500, 1000, 2000,
4000, 6000 and 8000 Hz. Only audiograms of the type A
were analyzed. Mean air conductivity HT for each ear for
all frequencies together was determined, and also sepa-
rately for the frequencies in the speaking area (250–
4000 Hz) and in the area of high frequencies (6000 and
8000 Hz). Common mean HT was calculated for each pa-
tient from values obtained for both ears separately, for all
frequencies together and separately for speaking area
frequencies and for high frequencies.
According to the Bureau International de Audiopho-
nologie normal HT comprises values from 0 to 20 dB.
Mild hearing loss have those with HT from 21 to 40 dB,
moderate from 41 to 70 dB, serious from 71 to 90 dB,
while patients with severe hearing loss have HT above 90
dB.29
Mean values for a set of laboratory parameters were
calculated from the results of regular checkups obtained
during the last year. Normal serum values were consid-
ered as follows: hematocrit (htc) 0.36–0.46 l/L for wo-
men, 0.41–0.55 l/L for men, determined using Coulter
Counter, automatic cell counter; calcium (Ca) 2.25–2.75
mmol/L, determined using colorimetry with ortocresol-
phtalein; phosphates (P) 0.60–1.40 mmol/L, determined
using molibdat UV method; alkaline phosphatase (AP)
from 40 to 110 U/L for women and 43–88 U/L for men,
determined by the method recommended by IFCC, using
AMP buffer; total proteins 65–85 g/L, determined using
Biuret spectrophotometry, modified by Henry with blind
serum test; albumin 35–52 g/L, determined using BCG me-
thod with brilliant cresil green; glucose 4.2–6.4 mmol/L,
determined using glucose oxidase PAP method; sodium
(Na) from 135 to 150 mmol/L, using method with ion se-
lective electrode; potassium (K) 3.6–5.6 mmol/L, deter-
mined by method with ion selective electrode; urea from
3.4 to 8.9 mmol/L, determined by enzymatic UV method
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with urease and glutamate dehydrogenase; creatinine
from 42 to 115 µmol/L, using enzymatic colorimetry PAP
method; albumin/globulins ratio; intact parathormon
(i-PTH) from 8 to 62 pg/mL, determined by ELSA PTH
immunoradiometric assay, GIF-SUR-YVETE CEDEX,
France). Single hemodialysis dose, Kt/V, was calculated
from predialytic and postdialytic urea, using equation ac-
cording to Jindal et al.30, (Kt/V = 4 × (U1 – U2/U1) –
1.2).
The obtained results were analyzed for the whole
group and for the subgroups according to age and to the
hemodialysis treatment duration. Mean values were ex-
pressed as means and standard deviation. Differences
were determined using Student’s t-test for independent
variables. Proportions were compared using c2-test. Sin-
gle correlations were examined. Differences at 5% and
1% levels were considered significant (p<0.05 and p<
0.01)31.
Results
There were 66 participants, 34 women and 32 men,
51.50±12.70 years of age (ranging from 21.45 to 70.90
years), treated by chronic HD for 69.70±53.80 months on
average (ranging from 3 to 263 months). Their mean HT
was 26±10.50 dB for all frequencies, 19.70±8.80 for fre-
quencies in the speaking area and 41.70±19.70 dB for
high frequencies (Table 1). Increased HT above 20 dB
(according to the Bureau International de Audiopho-
nologie29) was found in 42 patients (63.64%) for all fre-
quencies, in 22 patients (33.33%) for frequencies in the
speaking area and in 56 patients (84.85%) for high fre-
quencies. According to the severity of the hearing loss,
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TABLE 1
DEMOGRAPHICS, COMMON LABORATORY FINDINGS




Duration of chronic HD treatment (months) 69.7053.80
Hematocrit (L/L) 0.280.04
Total serum proteins (g/L) 71.705.10
Serum albumin (g/L) 40.603.70
Intact-parathormon (pg/mL) 263247
Serum calcium (mmol/L) 2.300.20
Serum phosphates (mmol/L) 2.300.65
Serum alkaline phosphatase (U/L) 104137
Serum creatinine (mol/L) 798193
Serum urea (mmol/L) 19.504.50
Kt/V 1.350.10
Hearing threshold (all frequencies) (dB) 26.0010.50
Hearing threshold (speech area) (dB) 20.009.00
Hearing threshold (high frequencies) (dB) 41.7019.50
TABLE 2
DIFFERENCE IN HEARING THRESHOLD (DB) BETWEEN CHRONIC HEMODIALYSIS PATIENTS YOUNGER THAN 45 YEARS (A) AND







All frequencies 19.305.90 28.6010.70 4.49 **s
Speech area 14.854.20 21.609.40 4.02 **s
High frequencies area 30.3016.15 46.3519.25 3.45 **s
Age (years) 35.257.80 58.057.10 11.06 **s
* p<0.05 ** p<0.01
TABLE 3
INCREASED HEARING THRESHOLD (ABOVE 20 DB) FREQUENCIES AMONG CHRONIC HEMODIALYSIS PATIENTS AND THE RELATED
DIFFERENCE BETWEEN YOUNGER THAN 45 YEARS (A) AND OLDER THAN 45 YEARS OF AGE (B)
All frequencies Speech area High frequencies area
n–% n–% n–%
A (n=19) 6–31.58 2–10.53 13–68.42
B (n=47) 36–63.16 20–42.55 43–91.49
Total (n=66) 42–63.64 22–33.33 56–84.85
÷²-test **11.85 *6.25 *5.60
p p<0.01 p<0.05 p<0.05
*p<0.05 ** p<0.01
there were 35 patients with mild (83.33%) and 7 patients
(16.67%) with moderate impairment. HT significantly
correlated positively only with the patients’ age (r=0.49,
p<0.01). There was not significant correlation between
HT and duration of HD treatment (r=0.03, p>0.05), nei-
ther between HT and laboratory parameters typical for
that group of patients.
The HD patients older than 45 years (n=47) had signi-
ficantly higher HT values in comparison with the youn-
ger patients (n=19) (Table 2). There was a significantly
higher proportion of patients with pathological value of
HT above 20 dB for all frequencies, for speaking area fre-
quencies and for high frequencies among the patients
older than 45 years than in the subgroup of youn- ger pa-
tients (Table 3).
The patients older than 60 years (n=23) had higher
HT for all frequencies and for higher frequencies in com-
parison with the subgroup of younger patients (n=43),
whereas HT for frequencies in the speaking area did not
differ between those subgroups (Table 4). There was a
significantly higher proportion of patients with patholog-
ical value of HT above 20 dB for all frequencies and for
high frequencies among the patients older than 60 years
than in the subgroup of younger patients, whereas the
difference was not significant for speaking area frequen-
cies (Table 5).
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TABLE 4
DIFFERENCE IN HEARING THRESHOLD (DB) BETWEEN CHRONIC HEMODIALYSIS PATIENTS YOUNGER THAN 60 YEARS (A)







All frequencies 23.6010.95 30.307.95 2.82 **s
Speech area 18.409.30 22.007.35 1.73 ns
High frequencies area 36.8510.50 50.8514.30 3.23 **s
Age (years) 44.7510.50 64.102.80 11.31 **s
* p<0.05 ** p<0.01
TABLE 5
INCREASED HEARING THRESHOLD (ABOVE 20 DB) FREQUENCIES AMONG CHRONIC HEMODIALYSIS PATIENTS AND THE RELATED
DIFFERENCE BETWEEN YOUNGER THAN 60 YEARS (A) AND OLDER THAN 60 YEARS OF AGE (B)
All frequencies Speech area High frequencies area
n–% n–% n–%
A (n=43) 21–48.84 11–25.58 33–76.74
B (n=23) 21–91.30 11–47.83 23–100.00
Total (n=66) 42–63.64 22–33.33 56–84.85
÷²-test **11.68 3.34 *6.30
p p<0.01 p>0.05 p<0.05
* p<0.05 ** p<0.01
TABLE 6
DIFFERENCE IN HEARING THRESHOLD (DB) BETWEEN SUBGROUPS DIVIDED ACCORDING TO CHRONIC HEMODIALYSIS (HD)











All frequencies 25.6011.10 26.1010.60 27.808.40 0.28 0.75 0.50
Speech area 20.009.40 19.908.70 17.807.20 0.05 0.75 0.71
High frequencies area 38.3019.10 42.0019.60 52.8020.00 0.73 1.92 1.39
HD treatment duration (months) 27.6014.90 83.8515.42 174.1047.00 **13.93 **9.21 **5.65
Age (years) 50.3013.20 51.4012.75 55.8010.55 0.31 1.29 1.02
*p<0.05 ** p<0.01
The subgroups formed according to the duration of
HD treatment (A – no longer than 60 months, B – from
61 to 120 months, C – longer than 120 months) neither
differed significantly in HT, nor in the proportions of pa-
tients with pathological HT above 20 dB (Tables 6 and 7,
resp.). Despite the difference in the duration of HD treat-
ment, those three subgroups did not differ in age (A –
50.30±13.20 years; B – 51.40±12.75 years; C – 55.80±10.55
years; tA:B=0.31, tA:C=1.29, tB:C=1.02, p>0.05 for each).
Discussion
The results of the study on hearing loss in the group
of 66 chronic HD patients, mean age 51.50±12.70 years
and treated with HD for 69.70±53.80 months on average,
showed that 42 of them (63.64%) had increased HT
above 20 dB. That proportion included pathological find-
ings for all categories of frequencies that were analyzed
by audiometry. According to the severity of the hearing
loss, mild impairments prevailed and were related to
more than 4/5 of the affected patients. The proportion of
the patients with hearing loss determined for speaking
area frequencies was significantly lower (22–33.33%)
than for higher frequencies (56–84.85%) patients. Audio-
metry and tympanometry showed that the found impair-
ments can be classified as sensorineural hearing loss.
Even more important is the finding that HT correlated
significantly positively with age (r=0.49, p<0.01) and did
not correlate either with the duration of HD treatment
(r=0.03, p>0.05) or with characteristic laboratory pa-
rameters. Older patients, both older than 45 and older
than 60, had higher HT, accordingly higher proportions
of pathological HT related to the older subgroups of pa-
tients. The results are in concordance with the data pub-
lished by most other authors7–8,32–33. Klingerman et al.32
found increased HT in 64% of their HD patients, with
the objection that they took a distinct cutoff value (15
dB) for pathological HT for area of frequencies between
250–4000 Hz whereas 20 dB for the frequencies between
6000 and 8000 Hz. Sensorineural hearing loss prevailed,
as it was recorded in 53.57% of the patients and related
to 83.33% of all cases of hearing impairments. In the
study of Santos et al.33 increased HT above 25 dB was de-
tected in 37.78% of their HD patients. Sensorineural or
other nature of the impairments was not specified. Sen-
sorineural hearing loss was found in 56% of HD patients
in the publication of Shaheen et al.8 and in 61.54% of
those studied by Bazzi et al.7.
Bazzi et al.7 found hearing impairment in 56% of their
patients which were younger than 45 years and in even
94% of the older. Gatland et al.20 published that ESRD
patients older than 50 years of age had significantly
greater hearing loss for higher frequencies area than the
younger.
As it was mentioned in the introduction chapter,
sensorineural hearing loss is characterized with equal af-
fection of both bone and air conductivity20, without so
called air-bone gap, with increased HT of 15 to 20 dB
above HT for healthy people, or above HT value for nor-
mal presbyacusis for certain age which is commonly
above 2000 Hz10. An important proportion of our pa-
tients, 63.64% of them (42 of 66) had that particular type
of sensorineural hearing loss. That finding is in part the
consequence of inability to exclude the cases of ototoxic
drugs side effects or concomitant presbyacusis, although
the study group was a selected one. According to Seid-
man et al.34 there was namely 23% of general population
between 65 and 75 years of age with presbyacusis, which
was very similar impairment as sensorineural hearing
loss in HD patients.
Many authors considered presbyacusis the hearing
loss caused by aging34–36, but they also stress the influ-
ence of genetic and environmental factors, socioeconomic
conditions and diet34, particularly folic acid and vitamin
B12 defficiency36. They also point out that hearing deteri-
orates with increasing age, but that there are some older
people with completely normal hearing ability37. There-
fore physiologic presbyacusis does not exist37.
If sensorineural hearing loss in ESRD is really caused
by preterm vascular aging, it remains difficult to explain
that even children with ESRD and with excluded oto-
toxic drugs influence also have that type of hearing loss
(30% of them)4–9,11–12.
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TABLE 7
INCREASED HEARING THRESHOLD (ABOVE 20 DB) FREQUENCIES AND THE RELATED DIFFERENCE BETWEEN SUBGROUPS
DIVIDED ACCORDING TO CHRONIC HEMODIALYSIS (HD) TREATMENT DURATION (MONTHS): A – SHORTER THAN 60, B –LONGER
THAN 60 AND SHORTER THAN 120, AND C – LONGER THAN 120
All frequencies Speech area High frequencies area
n–% n–% n–%
A (n=31) 21–67.74 10–32.26 23–74.19
B (n=26) 15–57.69 11–42.31 24–92.31
C (n=9) 6–66.67 1–11.11 9–100.00
Total (n=66) 42–63.64 22–33.33 56–84.85
÷²-test 2.76 2.96 5.47
p p>0.05 p>0.05 p>0.05
* p<0.05 ** p<0.01
Hearing ability did not differ among three subgroups
of our patients distributed according to the duration of
HD treatment (A – no longer than 60 months, B – from
61 to 120 months, and C – longer than 120 months). As it
was already mentioned, HT did not correlate with the
duration of HD treatment, very similar to the data pub-
lished by Antonelli et al.10 Furthermore, it is important
to point out that the three subgroups were not different
according to age, either. Bazzi et al.7 made the same
grouping by their patients (N=91) and found senso-
rineural hearing loss in 61.70% patients in the subgroup
A, 59.30% patients in the subgroup B and 64% in sub-
group C. They also found that mean HT and age were
comparable between the subgroups, and finally conclu-
ded that HD did not negatively affect hearing ability.
Neither we, not Bazzi et al.7 have audiograms from
the period before starting HD treatment. As some of
those patients are 10 years older now and HD itself did
not retard vascular aging, they must have had lower HT
by that preceded time. Their HT must have increased
with time due to vascular aging, but must not have
reached pathological values. Another possibility is that
the observed HD period is too short for significant vascu-
lar aging, and the third and the most probable explana-
tion is that hearing loss in chronic renal failure patients
is caused not only by preterm vascular aging, but also by
some other factors which might have benefited from HD.
In conclusion, our results along with other authors’
published data report on SNHL as very frequent finding
among chronic HD patients and suggest multifactorial
etiology. Accurate proportion of those with SNHL of un-
known origin is not possible to determine. Those cases
are probably not caused by uremic polyneuropathy and/
or preterm vascular aging only, although those factors
are likely to play crucial roles.
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SENZONEURALNA O[TE]ENJA SLUHA HEMODIJALIZOM LIJE^ENIH BOLESNIKA
S A @ E T A K
U kroni~nom bubre`nom zatajenju (KBZ) patolo{kim zbivanjem zahva}eni su svi organski sustavi. Nisu po{te|ena
ni osjetila, pa su tako ~esta i o{te}enja sluha, pogotovo senzoneuralna (SNOS). Etiologija nije jasna samo za dio njih, a
nazvana su »SNOS nepoznate etiologije« ili »uremijskom nagluhosti«. U ovom radu ispitivali smo prevalenciju SNOS
66 bolesnika prosje~ne dobi 51,50±12,70 godina, prosje~no hemodijalizom (HD) lije~enih 69,70±53,80 mjeseci. Inten-
zitet smo korelirali s dobi bolesnika, duljinom trajanja lije~enja i s nizom laboratorijskih parametara karakteristi~nih
za ovu skupinu bolesnika. Cilj nam je bio na}i mogu}e uzro~ne ~imbenike odgovorne za njegov nastanak. Povi{en prag
sluha (PS), iznad 20 dB, za sve frekvencije (prosjek 26±10,50 dB) imalo je 42, za frekvencije u govornom podru~ju
(prosjek 19,70±8,80 dB) 22, a u podru~ju visokih frekvencija (41,70±19,70 dB) 56 bolesnika. Na|ena je zna~ajna pozi-
tivna korelacija PS samo s dobi bolesnika (r=0,49, p<0,01). HD bolesnici, stariji od 45, odnosno od 60 imali su od
bolesnika mla|ih od 45, odnosno od 60 godina zna~ajno vi{e prosje~ne vrijednosti PS. Prema 2-testu me|u HD boles-
nicima starijim od 45, odnosno od 60 godina zna~ajno ~e{}e su bolesnici s patolo{kim PS. Prosje~ne vrijednosti PS u
podskupinama bolesnika odre|enim prema duljini trajanja HD lije~enja (A: do 60 mjeseci, B: 60–120 mjeseci, C: dulje od
120 mjeseci) nisu se zna~ajno razlikovale. U 3 navedene podskupine bolesnika nije bilo zna~ajno ~e{}e onih s patolo{kim
PS, a podskupine se nisu razlikovale ni po prosje~nim vrijednostima njihove dobi (A: 50,30±13,20 godina, B: 51,40±
12,75 godina, C: 55,80±10,55 godina). U zaklju~ku mo`emo, na osnovi vlastitih i rezultata drugih ispitiva~a re}i da su
SNOS HD bolesnika vrlo ~esta i da su posljedica niza ~imbenika. To~an udio bolesnika sa SNOS nepoznate etiologije
nemogu}e je odrediti. Vjerojatno ne nastaju samo zbog uremijske polineuropatije i/ili prerane vaskularne starosti iako
je vjerojatno da njima pripadaju vode}e uloge.
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